Tags Archive Navigation
icon
-
Featured NewsEnabling our associates to work safely on our sites
-
Featured NewsAsia Pacific Patient Innovation Summit examines capability building gaps of Patient Organizations
-
Featured NewsOne billion antimalarial treatments delivered: An extraordinary partnership journey
-
Featured NewsFDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)
-
Featured NewsIndustry and academia collaborating to innovate for patients
-
Featured NewsNovartis receives FDA fast track designation for sabatolimab (MBG453) in myelodysplastic syndromes
-
Featured NewsNovartis Entresto® indicated for treatment of hypertension in China
-
Featured NewsNovartis receives FDA Breakthrough Therapy designation for investigational 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC)
-
Featured NewsNovartis announces Complete Response Resubmission for inclisiran New Drug Application
-
Featured NewsNovartis receives FDA Orphan Drug Designation for NIS793 in pancreatic cancer
-
Featured NewsFDA accelerates review of Novartis STAMP inhibitor asciminib (ABL001) for patients with chronic myeloid leukemia (CML)
-
Featured NewsNovartis sabatolimab receives orphan drug designation from the European Commission for myelodysplastic syndromes
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 15
- › Next page